Key Findings From Recent Trials

Basic Alesse Information

• INN (International Nonproprietary Name): Levonorgestrel and Ethhinyl Estradiol.
• Brand Names Available In United Kingdom: Variants with the same INN are authorised in the EU/UK under multiple brand and generic names; the Alesse trade name is primarily used in Canada and North America but equivalent levonorgestrel/ethinyl oestradiol formulations appear in the UK market under other brand or generic labels.
• ATC Code: G03AA07.
• Forms & Dosages: Oral tablet formulations typically 0.1 mg levonorgestrel + 0.02 mg ethinyl oestradiol per active tablet; packaging commonly Alesse 21 (21 active) and Alesse 28 (21 active + 7 placebo).
• Manufacturers In United Kingdom: Not specified in the provided data; original manufacturer listed as Pfizer/Wyeth and generic suppliers include Apotex, Teva and Sandoz.
• Registration Status In United Kingdom: Variants with the same INN are marketed nationally in the EU/UK; check individual SPCs/SmPCs and MHRA/eMC records for specific brand authorisations.
• OTC / Rx Classification: Prescription Only (Rx) in all jurisdictions listed.

Worried whether levonorgestrel plus ethinyl oestradiol still looks like a safe, effective option?

Recent observational registries and pooled analyses between 2022 and 2025 have reinforced that low‑dose levonorgestrel/ethinyl oestradiol combined oral contraceptives provide reliable contraception when taken correctly.

Large cohorts show contraceptive failure rates comparable to other low‑dose combined pills, provided adherence is good.

Registry comparisons repeatedly identify a lower venous thromboembolism risk with levonorgestrel‑containing COCs than with some newer progestogens in head‑to‑head analyses.

Trials that focused on bleeding patterns favour standard 21/28 levonorgestrel/ethinyl oestradiol regimes for predictable withdrawal bleeding and fewer oestrogenic adverse events at 0.02–0.03 mg ethinyl oestradiol.

Pharmacovigilance through 2025 highlighted ongoing monitoring of VTE in higher‑risk groups and attention to mood changes, but no new organ‑specific toxicities were identified.

Practical trends in the UK include a shift towards generics, steady adherence improvement with 28‑day packs, and clinician preference for levonorgestrel COCs when seeking to mitigate baseline VTE risk.

Clinical Mechanism Of Action

Layman’s Explanation

What does this pill actually do to stop pregnancy?

It mainly prevents ovulation, so an egg is not released each cycle.

It also thickens cervical mucus, making it harder for sperm to reach an egg.

And it alters the uterine lining so implantation is less likely.

Scientific Breakdown

How the hormones work together.

Ethinyl oestradiol provides cycle stability and endometrial control.

Levonorgestrel is a synthetic progestogen that suppresses the hypothalamic–pituitary–ovarian axis via negative feedback.

Ovarian Suppression

Daily exposure to levonorgestrel (around 0.1–0.15 mg in various formulations) with ethinyl oestradiol (0.02–0.03 mg) reduces FSH and LH surges that are required for follicular maturation.

Anovulation rates are high with correct daily use, which is the main contraceptive effect.

Cervical Mucus & Endometrium

Levonorgestrel increases cervical mucus viscosity, creating a barrier to sperm transport.

Levonorgestrel plus ethinyl oestradiol also stabilises and thins the endometrium, reducing receptivity to implantation.

Pharmacokinetics are oral absorption with first‑pass hepatic metabolism, so enzyme inducers can reduce plasma steroid levels and efficacy.

This combination is classified as ATC G03AA07, reflecting a fixed systemic hormonal contraceptive.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Is this pill only for contraception?

Product data indicate the sole approved indication is contraception and the product is prescription‑only in all jurisdictions cited.

In the UK, formulations with this INN are available under several brand or generic names; the Alesse trade name itself is most notable in Canada but equivalent products circulate in the UK market.

These products are not authorised as emergency contraception.

Notable Off‑Label Trends

What do clinicians commonly do in practice?

Clinicians commonly prescribe levonorgestrel/ethinyl oestradiol COCs for cycle regulation, dysmenorrhoea and acne improvement, and occasionally as part of a strategy to manage heavy menstrual bleeding when combined with other measures.

Adolescent use after menarche follows standard adult dosing in practice.

Off‑label use should be supported by shared decision‑making, informed consent and documentation, and aligned with NICE and local formulary guidance.

Dosage Strategy

General Dosing

How should a typical pack be taken?

The standard regimen is one active tablet daily for 21 days followed by seven placebo tablets in 28‑day packs, or 21 active days then a tablet‑free interval for 21‑day packs.

Common tablet strength sold in the data is 0.1 mg levonorgestrel + 0.02 mg ethinyl oestradiol.

Start options include day‑1 start (immediate protection) or Sunday/start‑day protocols requiring seven days’ backup if not started on cycle day 1.

Condition‑Specific Dosing

Do teenagers or people with liver disease need different advice?

Adolescents may use standard adult dosing after menarche; the product is not for use before menarche or after menopause.

It is contraindicated in severe hepatic impairment and not recommended in renal failure.

Continuous use is possible but should be clinician‑guided, and special counselling is needed where obesity or interacting medicines present.

Missed‑pill guidance from product information: one missed active tablet — take as soon as remembered; two or more missed — take the most recent ASAP, discard other missed tablets and use backup contraception for seven days.

Safety Protocols

Contraindications

Who should not take this combined pill?

Absolute contraindications include active thromboembolic disease (DVT/PE), history of stroke or coronary artery disease, migraines with aura, current breast cancer or oestrogen/progestogen‑dependent tumours, uncontrolled hypertension, diabetes with vascular complications, severe liver disease or liver tumours, and known hypersensitivity to components.

Relative contraindications include obesity (BMI >30), smoking heavily (>15 cigarettes/day especially with increasing age), well‑controlled hypertension or diabetes, hyperlipidaemia, family history of VTE, gallbladder disease and chronic renal impairment.

Baseline checks in UK practice should document medical history, blood pressure, BMI and smoking status before prescribing.

Adverse Effects

What side effects should users expect?

Common adverse effects are nausea, breast tenderness, headache and spotting or irregular bleeding.

Less common effects include weight change, mood swings and decreased libido.

Red‑flag symptoms requiring urgent review are unilateral leg swelling or pain, breathlessness, acute chest pain, severe persistent headache, jaundice and severe abdominal pain.

Provide written information at dispensing and arrange regular review when appropriate.

Interaction Mapping

Food Interactions

Do I need to take the pill with food?

No clinically relevant food‑drug interactions are reported for levonorgestrel/ethinyl oestradiol, and meals do not affect dose timing materially.

Patients should be encouraged to take the tablet at roughly the same time each day to support adherence.

Drug Combinations To Avoid

Which medicines reduce contraceptive effectiveness?

Hepatic enzyme inducers such as rifampicin and rifabutin, certain anticonvulsants (carbamazepine, phenytoin, primidone), some antiretrovirals and herbal St John’s wort can reduce steroid levels and reduce effectiveness.

Protease inhibitors and some NNRTIs require specialist advice before co‑prescribing.

Broad‑spectrum antibiotics (excluding rifampicin) do not reliably reduce efficacy, but advise backup during prolonged diarrhoea or vomiting.

Refer to the MHRA and the BNF for up‑to‑date interaction lists before prescribing.

Patient Experience Analysis

Survey Data

What do users actually say about the pill?

Patient‑reported outcome studies show users value predictable cycles, lower oestrogen‑related side effects and tolerability, which often drives preference for levonorgestrel‑based pills.

Transient nausea, spotting in early cycles, mood changes and breast tenderness are common reasons for switching in surveys.

Most side effects settle within 2–3 cycles for many users.

Forum Trends

What are people asking online?

Forum searches show ongoing concern about brand availability — the Alesse name remains commonly used even where generics dominate — and frequent questions on weight, mood and VTE risk.

Social platforms also reveal users comparing levonorgestrel COCs with newer progestogens and considering alternatives such as Microgynon or Yasmin.

Clinicians should acknowledge anecdote but contextualise it with evidence showing a favourable safety profile for levonorgestrel COCs.

Distribution & Pricing Landscape

How do patients typically obtain this pill in the UK?

Levonorgestrel + ethinyl oestradiol products are prescription‑only and supplied via NHS prescriptions, private clinics and community pharmacies in the UK.

There is a clear market shift to generics, with companies like Teva and Sandoz supplying equivalent products; original makers include Pfizer/Wyeth.

On the NHS the cost to eligible patients is usually zero; private costs depend on pharmacy and prescription charges, with generics being inexpensive.

In our online pharmacy, alesse is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Pharmacies should store stock at recommended temperatures and monitor batches to avoid patient interruption.

Alternative Options

Comparison Table

Which alternatives are reasonable to discuss in consultation?

• Other COCs: Microgynon and Marvelon families (different progestogens), Yaz/Yasmin (drospirenone) — these differ chiefly by progestogen and may have different non‑contraceptive benefits and VTE profiles.
• Progestogen‑Only Pill (POP): For those with oestrogen contraindications.
• LARC: IUD/IUS and implants provide long‑acting reversible contraception without daily adherence demands.

Pros And Cons

How does levonorgestrel/ethinyl oestradiol stack up?

Pros include an established safety record, lower VTE risk than some newer progestogens and wide availability in affordable generics.

Cons include oestrogen‑related side effects in susceptible patients and contraindication in those with certain vascular risks.

For those unable to take oestrogen, POPs or LARC are preferred alternatives.

Choice should be made on efficacy, VTE risk, metabolic and mood profiles, and patient preference.

Regulatory Status

Is Alesse the same everywhere?

The combination of levonorgestrel and ethinyl oestradiol is classified under ATC G03AA07 and is prescription‑only in all jurisdictions listed.

In the UK, products with this INN are approved nationally and should be checked against their specific SmPC on the MHRA or eMC for up‑to‑date information.

The Alesse trade name is mainly used in North America, while equivalent formulations and generics are authorised in the EU/UK under various names.

Pharmacy dispensing must follow national prescribing rules and local formulary guidance, and any off‑label use should be documented and justified.

Consolidated FAQ

Is Alesse available on the NHS?

Equivalent levonorgestrel + ethinyl oestradiol formulations are available via NHS prescription, though brand names may vary.

Can I use it while breastfeeding?

Oestrogen‑containing combined pills are not usually recommended until at least six weeks postpartum and are often delayed while breastfeeding; consider the POP or LARC earlier where needed.

What if I miss two pills?

Take the most recent missed tablet as soon as you remember, discard other missed tablets, continue the pack and use backup contraception for seven days.

Can it be used for acne or heavy bleeding?

Clinicians commonly prescribe it for cycle control and acne off‑label; ensure informed consent is documented.

Is it emergency contraception?

No, it is not indicated for emergency contraception.

How should it be stored?

Store in the original blister at 15–30°C and protect from moisture; do not freeze.

Who cannot take it?

Refer to absolute contraindications such as active VTE, stroke, active breast cancer, severe liver disease and migraine with aura; consult the BNF or MHRA for complex cases.

Visual Guide

Which images help patients the most?

Provide a blister pack diagram showing the Alesse 28 layout (21 active pink then 7 placebo white) with day‑by‑day arrows for easy reference.

Include a simple mechanism infographic showing ovarian suppression, cervical mucus changes and endometrial effects with icons.

Use a red/amber/green contraindications flowchart for quick triage in clinical settings.

Offer a missed‑pill algorithm as a printable wallet card and a switching‑method timeline for clinicians handling method changes.

Ensure SVG/PNG web assets and high‑contrast PDFs for print, with concise alt text and translated versions where required.

Storage & Transport

How should the tablets be stored and handled?

Keep tablets in the original blister pack and store between 15–30°C, away from moisture and heat.

Do not freeze and avoid placing stock near sinks or radiators in the dispensary.

When posting or couriering, protect packs from extreme temperatures and follow import/export pharmaceutical rules for international consignments.

Advise patients to keep tablets in the blister until use and to return unused medication to the pharmacy for safe disposal.

Clinic stock should have batch logging and expiry checks in line with MHRA guidance on temperature excursions.

Guidelines For Proper Use

What should a clinician cover in a short consultation?

Confirm indication is contraception and take a full medical history including VTE/stroke, migraine with aura, smoking, BMI, liver disease and cancer history.

Measure baseline blood pressure and BMI and perform a pregnancy test if indicated.

Discuss the formulation options (21/28 packs), expected side effects and set expectations that the product is prescription‑only.

Explain start options and missed‑pill rules: one missed — take ASAP; two or more missed — take the most recent ASAP and use backup contraception for seven days.

Review interacting medicines such as enzyme inducers and advise on breastfeeding and postpartum timing.

Arrange a review and provide written information, and document informed consent for any off‑label uses.

Urgent review is required for suspected VTE, severe headache, jaundice or if pregnancy is suspected.

Delivery Across United Kingdom